永利度假村 WYNN 深 沪
已收盘 10-31 16:00:00 美东时间
118.99
-0.780
-0.65%
华盛通- 最 高120.05
- 今 开119.28
- 成交量 170.32万股
- 最 低 117.80
- 昨 收 119.77
- 总市值 123.75亿
- 52周最高 134.23
- 市盈率 静 27.33
- 换手率 1.64%
- 52周最低 64.75
- 委 比 31.05%
- 总股本 1.04亿
- 历史最高 228.56
- 量 比 1.42
- 振 幅 1.88%
- 历史最低 33.34
- 每 手 1
- 风险率 16.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wynn Resorts shares are trading higher in sympathy with Las Vegas Sands, which reported a Q3 earnings beat.
Wynn Resorts shares are trading higher in sympathy with Las Vegas Sands, which ...
10-23 23:20
How Is The Market Feeling About Wynn Resorts Ltd?
Wynn Resorts Ltd's (NYSE:WYNN) short interest as a percent of float has risen 1...
10-18 04:00
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Shares of casino stocks are trading lower in possible reaction to Macau Golden Week data.
Shares of casino stocks are trading lower in possible reaction to Macau Golden ...
10-13 23:24
美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
Shares of travel and leisure stocks are trading lower amid concerns of an imminent U.S. government shutdown. The industry may also be experiencing weakness due to worse-than-expected Consumer Confidence data for September.
Shares of travel and leisure stocks are trading lower amid concerns of an immin...
10-01 01:20
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
Stifel Maintains Buy on Wynn Resorts, Raises Price Target to $145
Stifel analyst Steve Wieczynski maintains Wynn Resorts (NASDAQ:WYNN) with a Buy and raises the price target from $130 to $145.
09-18 20:01
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
